drugset / Trial / NCT00294372
Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The general aim is to evaluate the antiviral activity and safety of increasing doses of oral administered RTV-boosted BILR 355 BS (75 mg and 150 mg twice daily) in HIV-1-infected, NNRTI-experienced patients, followed by 28 day combination therapy with Tipranavir or Lopinavir based HAART-regimen
Timeline
- Start
- 2006-02
- Primary completion
- 2007-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BILR 355 BS | Unknown | 75 mg | Oral |
| Subject | BILR 355 BS | Unknown | 150 mg | Oral |